ArticleJournal of inflammation research2026
The Inflammation Effect in the Association Between Bilirubin and Chronic Kidney Disease in Patients with Type 2 Diabetes: A Retrospective Cohort Study.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The associations of bilirubin (BIL) and systemic inflammation with chronic kidney disease (CKD) remain unclear. This study examined associations among BIL, systemic inflammation, and CKD progression in type 2 diabetes patients, assessing systemic inflammation's mediating role. Methods: This retrospective cohort study included 1215 subjects. The exposure was baseline BIL concentrations, while inflammation-related indicators including systemic inflammatory response index (SIRI) and systemic immune-inflammation index (SII). The main outcome was the first event of CKD progression, characterized by a decrease in the estimated glomerular filtration rate (eGFR) stage, with a sustained ≥25% decline in eGFR from baseline, confirmed by two consecutive measurements ≥3 months apart. Cox proportional hazards models assessed associations between BIL, systemic inflammation, and CKD progression. Subgroup and sensitivity analyses were also conducted. Restricted cubic splines (RCS), and mediation analysis were performed to assess the nonlinear associations and mediating role of systemic inflammation. Results: During a median follow-up duration of 2.00 years (interquartile range: 1.03-2.84 years), 153 participants exhibited progression of CKD. The RCS analysis indicated nonlinear associations between both total bilirubin (TBIL, Conclusion: Lower BIL levels (especially IBIL) were inversely associated with CKD progression risk in type 2 diabetes, with systemic inflammation partially mediating this relationship.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.